Log in to save to my catalogue

Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicent...

Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicent...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2340037436

Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan

About this item

Full title

Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan

Publisher

New York: Springer US

Journal title

Investigational new drugs, 2020-02, Vol.38 (1), p.172-180

Language

English

Formats

Publication information

Publisher

New York: Springer US

More information

Scope and Contents

Contents

Summary
Background
Conversion from sorafenib to regorafenib is primarily an evidence-based treatment strategy in patients with advanced hepatocellular carcinoma (HCC). This study aimed to assess the safety and efficacy of sequential therapy with sorafenib and regorafenib in patients with advanced HCC by analysis of outcomes in clinical practi...

Alternative Titles

Full title

Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2340037436

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2340037436

Other Identifiers

ISSN

0167-6997

E-ISSN

1573-0646

DOI

10.1007/s10637-019-00801-8

How to access this item